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Evaluation of a five-year predicted 
survival model for cystic fibrosis in 
later time periods
Theodore G. Liou1,2*, Christiana Kartsonaki3, Ruth H. Keogh4 & Frederick R. Adler1,5
We evaluated a multivariable logistic regression model predicting 5-year survival derived from a 
1993–1997 cohort from the United States Cystic Fibrosis (CF) Foundation Patient Registry to assess 
whether therapies introduced since 1993 have altered applicability in cohorts, non-overlapping in 
time, from 1993–1998, 1999–2004, 2005–2010 and 2011–2016. We applied Kaplan-Meier statistics to 
assess unadjusted survival. We tested logistic regression model discrimination using the C-index and 
calibration using Hosmer-Lemeshow tests to examine original model performance and guide updating 
as needed. Kaplan-Meier age-adjusted 5-year probability of death in the CF population decreased 
substantially during 1993–2016. Patients in successive cohorts were generally healthier at entry, 
with higher average age, weight and lung function and fewer pulmonary exacerbations annually. 
CF-related diabetes prevalence, however, steadily increased. Newly derived multivariable logistic 
regression models for 5-year survival in new cohorts had similar estimated coefficients to the originals. 
The original model exhibited excellent calibration and discrimination when applied to later cohorts 
despite improved survival and remains useful for predicting 5-year survival. All models may be used to 
stratify patients for new studies, and the original coefficients may be useful as a baseline to search for 
additional but rare events that affect survival in CF.
Survival of patients with cystic fibrosis (CF) has improved worldwide1–6. Improved care over the last 80 years 
increased the expectation of life at birth from a median of six months to approaching 50 years2,7,8. Patients, their 
families, friends and caretakers often compare individual age at death with the expectation of life at birth as a 
final measure of their efforts to extend a single life. However, this comparison is overly stringent and cannot 
account for individual circumstances that markedly change outcomes. If truly desired, one might look instead 
to the aggregated median age at death which reflects the age-distribution of the contemporary CF population, 
current mortality rates and the improving conditional survival from all ages as a result of rapidly improving ther-
apies3,9. Recently, this measurement rose to nearly 30 years2. Currently recommended10–13 beneficial treatments 
include pancreatic enzymes10,14, airway clearance15,16, mucolysis17–19, inhaled antibiotics20–22, anti-inflammatory 
agents23,24, and CF transmembrane regulator protein (CFTR) modulators25–27. Although gains have been tremen-
dous, CF survival continues to fall short of the approximately 80 year expectation of life for the average newborn 
in the United States28,29, providing continued motivation to improve treatments2.
To help clinicians better understand relative survival associations of different demographic and disease-related 
factors, we previously developed and tested a 5-year predictive survivorship model for CF30 using a cohort of 
patients alive and enrolled on January 1, 1993 in the US CF Foundation Patient Registry (CFFPR) followed 
through 1997 (Table 1). Because part of the original intent was to create a clinically useful tool, we chose logistic 
regression which most easily produces a single risk assessment derived from multiple but readily obtained meas-
urements at the point of care.
The most important single variable is the forced expiratory volume in 1 second (FEV1), a measurement of 
airway physiology, expressed as the percent predicted FEV1 (FEV1%) estimated from each patient’s age, sex, 
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height, race and ethnicity31,32. Every percentage point higher value of FEV1% indicates a 4% reduction in 5-year 
risk of death on average, all other factors being equal (odds ratio, OR = 0.96, 95% Confidence Interval [CI] 
0.957–0.968, P < 0.001). Burkholderia cepacia has the highest impact of any single factor implying that the infec-
tion increases the risk of death more than six-fold (OR = 6.20, 95% CI 3.42–11.23, P < 0.001). Fortunately, the 
number of patients with this infection was small in 1993 (and remains small, Table 2). The size of the effect of 
B cepacia is partially explained because of an interaction with the number of pulmonary exacerbations in the 
year prior to evaluation. Each observed pulmonary exacerbation signals a 59% increased risk of death within 
5 years (OR = 1.59 per exacerbation, 95% CI 1.50–1.69, P < 0.001). The interaction term indicates that pulmo-
nary exacerbations have a smaller expected survival effect in the presence of B cepacia infection. Thus, exacerba-
tions in patients with B cepacia infection have an effect that is reduced by about a third by the interaction term 
(OR = 0.67, 95% CI 0.53–0.84, P = 0.001) compared to exacerbations in the absence of that infection. A diagnosis 
of CF-related diabetes (CFRD) has the same effect on 5-year predicted survival as a 12 percentage point reduction 
in FEV1% (OR = 1.63, 95% CI 1.21–2.21, P = 0.001). The finding quantified the high impact of the diagnosis in 
CF33,34. Two variables were included in the original multivariable model despite high P values, Staphylococcus 
aureus infection (OR = 0.81, 95% CI 0.64–1.02, P = 0.07) and pancreatic sufficiency (OR = 0.635, 95% CI 0.35–
1.16, P = 0.14) for two reasons. First, they are prominent features of the clinical syndrome that are useful signals 
of health and disease as commonly assessed in isolation at the bedside, and, second, these variables substantially 
improved the fit of the overall model to the data.
Clinicians and researchers currently use the model to understand survival implications. For example, Rubin 
et al.29 projected long-term survival outcomes of CFTR modulator use for patients homozygous for F508del 
mutations using the original 5-year predicted model using the coefficients from the proportional hazards version 
of the model30.
Since 1993, death rates with CF have dramatically decreased2, the majority of effective CF-specific therapies 
were introduced17,18,20,21,24–27, and the CFFPR itself was extensively edited to improve data quality and comply 
with current privacy and data use practices1. Considering these changes, we examined shifts in the distributions 
of factors underlying 5-year survival and assessed prediction model usefulness. The original model incorporated 
commonly measured and recorded clinically important variables on which clinicians continue to focus. Thus, 
we evaluated the original variables in CFFPR-derived patient cohorts from later time periods, examined model 
discrimination and calibration and considered the need for modifications.
Methods
Data. This study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. 
The University of Utah Investigational Review Board (IRB) assessed the ethics of our procedures and approved 
our study. After review, we requested the CFFPR 1986–2015 supplemented by 2016 outcomes data from the US 
CF Foundation (Bethesda, MD, USA). CFFPR data are collected from patients or their guardians after written 
informed assent (if 12–18 years old) and consent. All data are acquired with local IRB approval in accredited US 
CF care centers and affiliate programs2.
Study design. To assess original model performance30, we selected patients from the CFFPR who were alive 
and seen at least once in 1993, 1999, 2005 or 2011 to create new cohorts to compare to the original cohort. Using 
the original patient selection criteria30, we created a new 1993–1997 cohort with January 1, 1993 as the time origin 
with follow up until December 31, 1997 or death for comparison with the original cohort to better understand 
data cleaning effects1. Patients without death dates were censored on December 31, 1997.
We used first encounter dates during 1993, 1999, 2005 or 2011 as the cohort time origins for 1993–1998, 
1999–2004, 2005–2010 and 2011–2016, respectively, with follow up to death or last encounter within five years 
of the entry date. Loss to follow up was defined as having a final recorded contact with a patient before the end of 
5 years of follow up for any study cohort without a record of death. These individuals were included as members 
Variables
Parameter 
Estimates (log 
odds ratios)
Standard 
Errors
Odds Ratio  
(95% Confidence 
Interval) P value
Intercept −1.93 0.27 0.14 (0.08–0.25) < 0.001
Age (per year) 0.028 0.0060 1.03 (1.02–1.04) < 0.001
Sex (male = 0, female = 1) 0.23 0.10 1.26 (1.04–1.53) 0.018
FEV1% (per %) −0.038 0.0028 0.96 (0.96–0.97) < 0.001
Weight-for-age z Score −0.40 0.053 0.67 (0.6–0.74) < 0.001
Pancreatic sufficiency (0 or 1) −0.45 0.31 0.64 (0.35–1.16) 0.141
Diabetes mellitus (0 or 1) 0.49 0.15 1.63 (1.21–2.21) 0.001
Methicillin sensitive Staphylococcus aureus (0 or 1) −0.21 0.12 0.81 (0.64–1.02) 0.067
Burkholderia cepacia (0 or 1) 1.82 0.30 6.20 (3.42–11.23) < 0.001
Number of prior year acute exacerbations (0–5) 0.46 0.031 1.59 (1.5–1.69) < 0.001
Interaction between prior year acute exacerbations and B. cepacia −0.40 0.12 0.67 (0.53–0.84) 0.001
Table 1. Multivariable Logistic Regression 5-Year Predicted Survival Model, US CFFPR, Originally Published 
1993–1997 Cohort*. *Reproduced with permission and modified by reversal of sign of parameter estimates to 
predict deaths rather than survival and addition of 95% confidence intervals with P values30.
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of the group who remain alive at the end of each 5-year cohort study period. To address potential impact of loss 
to follow up during each cohort period, we treated censored patients as having died in sensitivity analyses. The 
1993–1998 cohort allows assessment of using actual encounter dates for study inclusion compared to the original 
1993–1997 cohort30.
The 5-year survival model30 includes nine variables, of which some require calculation from underlying vari-
ables (Table 1). For inclusion in a cohort, patients had to be at least 6 years old at one or more clinic encounters in 
the first year of each cohort, 1993, 1999, 2005 or 2011. At the baseline encounter for each cohort, patients needed 
height, weight and FEV1 measurements, pulmonary exacerbation counts for the prior year, pancreatic sufficiency 
status, CFRD status and sputum culture data including methicillin-sensitive Staphylococcus aureus (MSSA) and 
Burkholderia cepacia complex infections. Repeating our prior method30, we excluded patients if they received 
lung transplantation during or prior to each cohort period for the main analysis and had no other specific exclu-
sion criteria. We repeated the entire analysis to understand the sensitivity to inclusion of patients who underwent 
lung transplantation during each cohort period.
Initial data processing. We applied National Health and Nutrition Examination Survey (NHANES) III 
equations31 to the best FEV1 upon or in the year prior to cohort entry to derive FEV1% as these were the values 
primarily used during the periods of study and in the previous publication30. We used more recent Global Lung 
Initiative (GLI) equations32 to re-calculate FEV1% to assess the potential impact on results and interpretations 
due to the potential change in patients studied due to the differing availability of equations for specific ethnic 
and racial backgrounds. We used patient age on the date of start of follow up and the highest FEV1, worst micro-
bial culture results and count of pulmonary exacerbations in the year prior to the start of follow up. We used 
reported insulin and pancreatic enzyme treatments as indicators of CFRD and pancreatic sufficiency, respectively. 
Weight-for-age z-score was calculated as done previously30,35,36.
We developed a method to identify and correct weight, height and FEV1 values that appeared incorrect for 
reasons such as recording values in incorrect units (for example, 182 cm measured as 72 inches and reported as 
72 cm) or entering wrong values (for example, misrecorded digits such as 182 cm recorded as 82 cm or as 128 cm). 
These types of mistakes are usually identifiable with review of patient-specific longitudinal data but are often within 
Original 1993–1997 
Cohort, n = 11,63030
New 1993–1997 
Cohort, n = 9,941
New 5-Year Cohorts*
1993–1998, n = 9,757 1999–2004, n = 13,073 2005–2010, n = 15,043 2011–2016, n = 17,635
Deaths within 5 years: % 12.7 12.2 † 13.2 † 10.0 ‡ 7.5 ‡ 7.3 ‡
Age: Median (Range) 15.42 (5.50–71.05) 15.37 (6.00–71.05) † 15.44 (6.00–66.47) † 15.29 (6.01–72.15) † 16.25 (6.00–74.31) § 17.93 (6.00–81.14) §
Sex: % Female 46.6 46.8 † 46.8 † 47.0 † 47.6 † 48.5 ǁ
FEV1%: Median (Range) 67.94 (5.11–191.46) 70.92 (6.02–184.13) ** 74.52 (6.02–184.13) ** 85.79 (9.52–174.36) ** 88.49 (14.57–178.99) ** 91.43 (11.00–196.24) **
Weight-for-age z-score: Mean 
(SD) −0.85 (1.06) −0.83 (1.05) 
† −0.76 (1.05) § −0.46 (1.00) § −0.25 (1.01) § −0.08 (1.00) §
Pancreatic Sufficiency: % 
Affected 5.3 6.3 
†† 4.2 ‡ 4.5 †† 6.1 †† 9.7 ‡
Diabetes: % Affected 6.2 6.3 † 7.0 §§ 9.5 ‡ 14.6 ‡ 21.1 ‡
Methicillin Sensitive S aureus: 
% Infected 30.8 30.9 
† 36.3 ‡ 48.6 ‡ 61.1 ‡ 61.3 ‡
B cepacia complex: % Infected 3.6 3.7 † 4.0 † 3.9 † 3.7 † 3.9 †
Prior Year Pulmonary 
Exacerbations: Median 
(Range)
0 (0–5) 0 (0–5) ‡ 0 (0–5) ‡ 0 (0–5) ‡ 0 (0–5) ‡ 0 (0–5) ‡
% with Number 
of Pulmonary 
Exacerbations‖‖
0 51.7 59.6 59.3 66.5 59.5 59
1 19.5 17.3 17.5 11.7 23.2 22.3
2 12.8 10.8 10.8 10.2 9.2 10.4
3 6.8 5.5 5.5 4 4 4.3
4 3.9 3.3 3.3 3 2.2 1.9
5+ 5.3 3.6 3.6 4.6 2 2.2
Prognostic risk score: Mean 
(SD)*** −3.10 (1.94) −3.30 (1.83) −3.43 (1.84) −3.98 (1.81) −4.18 (1.69) −4.26 (1.73)
Prognostic risk score: Median 
(Range)*** −3.29 (−8.89–2.71) −3.51 (−8.83–2.37) −3.65 (−8.83–2.07) −4.28 (−9.57–2.12) −4.43 (−10.71–1.64) −4.50 (−10.16–1.79)
100 × Predicted Probability 
of Death within 5 Years Using 
the Original Model: Median 
(Range)
3.597 (0.014–93.76) 2.902 (0.015–91.45) 2.535 (0.015–88.77) 1.359 (0.007–89.27) 1.177 (0.002–83.75) 1.098 (0.004–85.68)
Table 2. Baseline Characteristics of US CFFPR Cohorts, 1993–2016. *Comparisons used corrected data for 
FEV1, height and weight and weight-for -age z-score, prognostic risk score and predicted probabilities of death 
calculated using those corrected values. Compared to original 1993–1997 cohort †P-value not significant;  
‡P < 0.001 by χ2; §P < 0.001 by t-test; ‖P = 0.001 by χ2; **P < 0.001 by Mann-Whitney-Wilcoxon test; ††P < 
0.01 by χ2; §§P < 0.05 by χ2. ‖‖Statistical comparisons were not made for percentages of patients with each 
Number of Pulmonary Exacerbations. See main text paragraph in Results concerning prognostic risk scores. 
***Prognostic risk score is the equivalent to the log-odds of death within 5-years.
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physiologically normal ranges (Fig. S1). To standardize the process, we fitted generalized additive models (GAM)37,38 
to identify weight, height and FEV1 values unlikely to be correct. For each patient, we treated height, weight and 
FEV1 as dependent variables and age as the independent variable. For each fit, we computed the standard deviation 
of the residuals and used this to find the z-score for the residual for each individual data point. We removed values 
with absolute z-scores greater than 3 for height and 4 for weight. We repeated the fits and removal of values with 
absolute z-scores greater than 3 or 4 on each successive fitting until no outstanding values remained. For FEV1, we 
did not correct values with negative z-scores because acute decreases are expected with pulmonary exacerbations. 
We used a z-score cutoff of 4 to identify high values likely to be incorrect without falsely identifying similar values 
following lung transplantation. We used the final individual GAM fits to estimate replacement values for height, 
weight and FEV1 values flagged as incorrect. However, we did not correct first or last values to avoid extrapolation 
outside the bounds of measured data. The main analysis used data from patients with complete data sets after cor-
rections, but we repeated the analyses three times to understand model sensitivity to using complete data sets with 
(1) uncorrected but physiologically plausible, (2) corrected or (3) corrected and imputed data.
Statistical analysis. We calculated Kaplan-Meier 5-year death rates for the four new cohorts, using each 
patient’s first encounter with complete data as the time origin. We summarized each predictor variable included 
in the original model and tested for differences between the original 1993–1997 cohort and all other cohorts. We 
examined each disease characteristic in the whole CFFPR by year to understand whether changes in distribution 
of values were isolated to study cohorts only39,40. We further evaluated year-to-year changes in CFRD prevalence 
using a multivariable model using generalized estimating equations with an independence working correlation 
matrix with CFRD as the outcome variable and age as the input variable adjusted by FEV1%, weight-for-age 
z-score and CFFPR year of study41,42.
We assessed model discrimination and calibration43,44. We used the original model30 to calculate a prognostic 
risk score in the new cohorts defined for individual i as
= + + + +p b b x b x b x , (1)i 0 1 1 2 2 10 10i i i
where …x x, ,1 10i i denote the values for individual i of the variables included in the original model (including the 
interaction term, Table 1), b0 is the model intercept, and b1, …, b10 are the estimated parameters (log odds ratios) 
from the original model corresponding to each variable. For patient, i, the predicted probability of death during 
5-year follow-up is given by =
+
PRi
e
e1
pi
pi
. We compared the distribution of the prognostic risk score across the 
new cohorts. To assess model discrimination, we derived the area under the receiver operating characteristic 
(ROC) curve or C-index45,46.
To assess model calibration, we divided subjects for each study cohort into 10 sub-groups, indexed by g , based 
on predicted probabilities of death PRi(0–0.1, 0.1–0.2,…,0.9–1) and calculated the expected number of deaths 
within each sub-group during follow-up, = ∑ ∈E PRg i g i, and compared to the observed number of deaths both 
graphically and using a χ-squared test with 9 degrees of freedom47,48. To further assess model calibration, we fit-
ted a logistic regression model in each cohort, with the indicator of 5-year mortality as the outcome for each 
patient, Yi, and the prognostic risk score as the predictor:
α α
=
− =
= + .log Pr Y
Pr Y
p( 1)
1 ( 1) (2)
i
i
0 1 i
In a perfectly calibrated model, the intercept (α0) and slope (α1) from the regression should be 0 and 1, respec-
tively44,49. We considered two approaches50 to further assess and improve the performance of the original model 
using the original 9 covariables and 1 interaction term for the five new cohorts:
(1) The calibration intercept method allows a different intercept for the prognostic model in each new cohort, 
by changing the value of b0 in Eq. 1. The new intercept is α +ˆ b0 obtained by fitting model (2) with the slope (α1) 
fixed at 1. An estimate with α <ˆ 00  indicates that the predicted probabilities obtained from the model are system-
atically too high while α >ˆ 00  indicates they are too low. The modified prognostic risk score is:
α= + + + + + .^p b b x b x b x (3)i
(1)
0 0 1 1 2 2 10 10i i i
(2) The calibration intercept and slope method systematically alters parameters b1, …, b10 in Eq. (1) by a con-
stant multiplicative factor and derives a new intercept in place of b0. The calibration intercept and slope are 
obtained by fitting model (2), and the prognostic risk score is:
α α= + + + + + .^ ^p b b x b x b x( ) (4)i
(2)
0 1 0 1 1 2 2 10 10i i i
Under each method we compared expected and observed probabilities of 5-year survival in 10 risk sub-groups 
as described above47.
We used the statistical system R to create study cohorts and perform all analyses51.
Results
The CFFPR 1986–2016 contains data from 307 US CF Foundation accredited care center programs on 48,976 
patients reported annually for 1986–1993, quarterly for 1994–2002 and with each of 1,771,761 clinical encounters 
for 2003–2015. Among these patients, 29,251 met inclusion criteria for one or more of the study cohorts formed 
in 1993, 1999, 2005 and 2011 (Table 2). Application of GLI32 rather than NHANES III equations31 on directly 
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measured forced expiratory volume in one second (FEV1) values to derived percent predicted FEV1 (FEV1%) 
did not substantially change the patterns of inclusions or exclusions. The primary reasons for exclusion were age 
less than 6 years, missing data or lung transplantation (Table S1). Missingness increased with identification of 
incorrectly recorded values for height, weight and FEV1, but sensitivity analyses using uncorrected, corrected, 
or corrected and imputed data produced no evidence that data were not missing completely at random. Further 
sensitivity testing by inclusion of patients undergoing lung transplantation during each study cohort period had 
no substantial effect on results and no effect on interpretations.
The new 1993–1997 cohort has few changed characteristics relative to the original published 1993–1997 
cohort. We found a small clinically unimportant increase in FEV1% values, more frequent pancreatic sufficiency 
and fewer pulmonary exacerbations (Table 2) suggesting that data cleaning since the original analysis1 does not 
substantially affect the applicability of the original model publication30.
However, the distributions of patient characteristics for the more recent and new 5-year cohorts differ from 
the original 1993–1997 cohort. Most changes reflect improving trends in the CFFPR (Fig. 1A–D, F–H). In con-
trast, CF-related Diabetes mellitus (CFRD) prevalence as a function of age worsened (Fig. 1E) by about 9% per 
year (P <0.001, Table S2), a finding unexplained in multivariable analysis by increasing FEV1% (Fig. 1B) or 
weight-for-age z-score (Fig. 1C), which are negatively52 and independently associated (Table S2) and incompletely 
explained by modestly improving detection34.
The distribution and range of individual prognostic risk scores (log-odds ratios for death within 5-years) 
derived using the original 5-year predicted survival model (Table 1)30 were similar between all new cohorts and 
the original 1993–1997 cohort (Table 2). There was no significant difference between the prognostic risk scores 
from the new 1993–1997 cohort relative to those from the original. Scores for successive cohorts tended to be 
lower on average. Estimated Kaplan-Meier 5-year death probabilities decreased with successive study cohorts 
(Fig. 2), although without adjustment, differences could partially be due to age distribution changes at the start 
of each cohort. Nevertheless, histograms of prognostic risk scores and predicted probabilities showed similar 
distributions with no obvious outliers (Fig. S2). Refitting the 5-year multivariable logistic regression prediction 
model produced new model coefficients similar to published coefficients (Fig. 3 and Table S3), with the exception 
of the intercepts indicating that associations between predictors and outcomes remained approximately stable in 
the new study cohorts (Fig. 4). A small percentage of patients were lost during each cohort prior to reaching a full 
5 years of follow up (Table S1 and Fig. S3). When we treated patients lost to follow up as having died rather than 
alive, we obtained similar model coefficients and predicted probabilities compared to those derived from treating 
those patients as alive at the end of the 5 years.
When we applied the original model to new cohorts, the C-Index ranged from 0.87 to 0.91 demonstrating 
high discriminative power (Fig. S4) similar to the C-Index of 0.89 in the original 1993 validation cohort (Fig. 
S5). Calibration was best in the 1993–1997 validation cohort with similar numbers of expected and observed 
deaths within sub-groups defined by risk scores (Table S4). Expected tended to be lower than observed numbers 
of deaths, with increasing differences with successive cohorts due to a bias towards over-optimistic estimates of 
predicted survival due to exclusion of transplanted patients (see limitations section of Discussion).
Table 3 shows results from logistic regression of death within 5-year follow-up on the prognostic score, using Eq. (2). 
Under a well calibrated model we should find an intercept of 0 (α = 00 ) and a slope of 1 (α = 11 ), as seen with the 
1993–1997 validation cohort. The estimated slopes are close to 1 in all new cohorts, but the intercepts are greater than 
zero, indicating that original model predicted probabilities are too low. This also holds when the slope is fixed to be 1.
Findings from calibration assessments and similarities between coefficients in new models derived from new 
cohorts suggest that modifying the intercepts alone (Fig. 4) or both intercepts and slopes in the prediction model 
(b0 and α1, respectively) would improve the performance of the original model in the new cohorts. Modified 
intercepts alone, thus using α0 estimates with α1 set to 1 from Eq. (2), produced modified prognostic risk scores 
using Eq. (4) that improved model calibration in all new cohorts (Table S5). For the two most recent cohorts, 
modifying intercepts alone produced better calibration than using both new intercepts and slopes by using α0 and 
α1 estimates from Eq. (2) (Table S6).
Sensitivity analyses showed similar results using data with no attempts to correct potentially incorrect data with 
values within physiologic limits (for example accepting a physiologically plausible height of 165 cm without further 
testing vs deleting a recorded height of 1,650 cm) or using data after imputation of missing data for height, weight 
and FEV1. Results were similar whether using NHANES III31 or GLI32 equations to calculate FEV1%, although the 
choices of equations select somewhat different sets of study patients due to racial or ethnic differences. For example, 
patients of Asian race are excluded when using NHANES III while Hispanic ethnicity cannot be considered when 
using GLI to derive FEV1% because of the lack of applicable equations for race or ethnicity. Additional sensitivity 
analyses showed similar results when including patients who underwent lung transplantation during each cohort.
In summary, the prediction model has excellent discrimination in new cohorts. Model intercept modifica-
tions improve the calibration and accuracy of predicted probabilities of death within 5 years especially for recent 
cohorts. From Eq. (4), the modified intercept for the 2011 cohort is −1.38 which produces the most appropriate 
model for use today depending on the application (Original Model with Modified Intercept, Table S3).
Discussion
We evaluated a previously published 5-year predicted survival model of CF and found that it remains a useful 
prediction model in updated cohorts. However, performance improved with adjustment of the model intercept 
to account for overall improvements in mortality rates over time. Coefficients for each included variable derived 
from new cohorts were similar (Fig. 3 and Table S3) showing that associations between demographic factors and 
measures of disease state remain largely unchanged despite 5-year survival improvements over time (Fig. 2). 
After intercept adjustment, the original 5-year prediction model has excellent calibration (Fig. 4 and Table S5), 
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unchanged clinical implications and equally good discrimination for all new patient cohorts (Fig. S4 and Fig. 
S5). Five-year survival probabilities for CF improved because of slowing disease progression and shifts in dis-
tributions of most survival predictors (Fig. 1). These findings suggest that the original unmodified 5-year pre-
dicted survival model remains useful for stratifying individuals into expected survival groups for observational or 
Figure 1. Prevalence of Conditions Predictive of 5-Year Survival in the US CFFPR, 1993–2015. Variables 
included in the original 5-year survival prediction model were evaluated by Registry year through 2015 for 
every age. (A) Sex distribution, (B) FEV1%, (C) Weight-for-Age z-score, (D) Pancreatic Sufficiency status, (F) 
Methicillin sensitive S aureus (MSSA) infection status, (G) B cepacia complex infection status, (H) Number 
of Pulmonary Exacerbations in the Prior Year all changed in directions consistent with improved long term 
survival. Of the variables in the original model, only (E) CF-Related Diabetes status worsened.
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interventional studies of CF29. Worksheets allow comparisons of survival predictions using original and modified 
models (Table S7). The model with modified intercept is more useful for applications where precise comparisons 
between individual predictions and outcomes are needed, for example, for investigation of the survival impact of 
lung transplantation53,54 in a setting of markedly improved survival with CF.
In the current study, all covariates included in the 5-year model except diabetes improved (Fig. 1), favoring 
better survival on average within each successive cohort. Some patients remain at every disease level, although the 
proportion of patients in the most severe states of disease continue to decrease (Table 2).
Unexpectedly, diabetes was more common at every age in each succeeding year of the CFFPR (Fig. 1e). By the 
end of the study period, the roughly 15% increase in CFRD was associated with an increase in mortality equal to 
approximately 20% of the observed decrease in mortality.
Multiple mechanisms cause CFRD including physical destruction of pancreatic β-islet cells from inflam-
mation55, modifier gene influences56,57 and CFTR dysfunction itself58,59. Sustained increases in CFRD preva-
lence (Fig. 1E) may stem partially from competing influences of modestly improving CFRD detection2,34, mild 
Figure 2. Unadjusted Kaplan-Meier Survivor Curves, US CFFPR, 1993–2016.
Figure 3. Coefficients from Re-Derivation of 5-Year Multivariable Logistic Regression Models by Cohort from 
the US CFFPR, 1993–2016. Coefficients with 95% confidence intervals are shown as derived from applying 
multivariable logistic regression to the cohorts studied: original 1993–1997 (derivation and validation cohorts 
combined)30, new 1993–1997, 1993–1998, 1999–2004, 2005–2010, 2011–2016.
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phenotype frequency and weight-for-age z-score. However, improving survival may allow better observation of a 
direct effect of CFTR dysfunction suggesting that modulators of defective CFTR25,26 may modify CFRD pathogen-
esis and that CFRD biomarkers might be novel reporters to help guide use of these new agents. CFTR modulators 
may treat or prevent CFRD itself independently of lung disease.
The prediction model was fitted using logistic regression modeling of patients with complete data with and 
without methods to account for missing and incorrect data. Loss to follow up in the CFFPR was recently eval-
uated in a 2009–2013 cohort and involved less than 10% of patients1. We found similar occurrences of loss to 
follow up in our cohorts (Table S1, last row and Fig. S3). Sensitivity analyses using the four cohorts, 1993–1998, 
1999–2004, 2005–2010 and 2011–2016 and treating patients who were lost to follow up as having died rather 
than as alive at the end of the 5-year period resulted in similar model coefficients and similar fits to the data 
with no effect on interpretation of our results. Independent evaluation found nearly complete clinical data for 
2003–2009 and missingness of no more than 4.2% of death dates60. The high follow-up rates and low proportion 
of individuals lost to follow-up in the CFFPR data1,60 probably explain the lack of material differences between 
using uncorrected and corrected data and suggest that finding patients previously missing from the CFFPR may 
provide no further substantial changes in the prediction model.
The high degrees of model discrimination and calibration suggest that further improvements to the model 
by simply adding new variables to the model may be difficult. Addition of variables of high interest in the CF 
community include assessments of liver disease61, renal dysfunction62, arthropathy54 as well as severe and acute 
but unusual or rare events such as massive hemoptysis63 and pneumothorax64. Within the CFFPR, addition of any 
of these variables to the current logistic regression model eliminated large numbers of patients from assessment 
Parameter
1993–1997 
Validation Cohort, 
n = 5,810
New 1993–1997 
Cohort, n = 
9,941
New 
1993–1998, 
n = 9,757
New 
1999–2004, 
n = 13,073
New 
2005–2010, 
n = 15,043
New 
2011–2016, 
n = 17,635
Using Eq. (2)
α0 0.046 (0.062) 0.33 (0.055) 0.62 (0.058) 0.74 (0.060) 0.59 (0.066) 0.64 (0.062)
α1 1.00 (0.034) 1.05 (0.027) 1.06 (0.027) 1.06 (0.025) 1.03 (0.025) 1.04 (0.024)
Using Eq. (2) with α1 fixed to be 1
α0 0.029 (0.047) 0.26 (0.037) 0.52 (0.036) 0.61 (0.035) 0.53 (0.036) 0.54 (0.033)
Table 3. Assessments of Model Calibration in New Cohorts from the US CFFPR, 1993–2016*. *Results from using 
two strategies to assess model calibration are shown. See Statistical Analysis in Methods following Eq. (2). Results are 
shown as “Estimate (Standard Error).” Prognostic risk score is equivalent to log-odds of death within 5 years.
Figure 4. Comparisons of Observed and Expected Deaths for Studied Cohorts Using the Original 5-Year 
Predicted Survival Model, US CFFPR, 1993–2016. Observed and Expected deaths were derived by creating 
deciles of patients for Hosmer-Lemeshow testing. The fractions of deaths within each decile sub-group are 
plotted. (A) shows the discrimination performance of the original 5-year predicted survival applied to each of 
the cohorts studied in this work. (B) shows the effect of modifications of intercepts for each cohort.
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due to missingness of data, sometimes exceeding 50% of the patients included in the current study. This degree of 
missingness introduced severe bias to the analysis of survival (not shown).
Expansion of the model with novel variables is highly desirable but must avoid introduction of bias from 
exclusion of large numbers of patients with missing data. Inclusion of sufficient relevant events to assess variables 
in addition to those in our original multivariable model may be feasible using methods that incorporate longi-
tudinal follow up over extended periods. Such a model could allow inclusion of sparsely collected or observed 
events such as pneumothorax and quantitatively relate their effects to those of more common factors such as low 
FEV1%. The present work, by demonstrating the stability of the 5-year predicted survival model using 5 cohorts 
collectively followed for over 24 consecutive years, provides the foundational work that supports the feasibility of 
such a longitudinal approach.
Some improvements to the prediction model might also be achieved by incorporating non-linear functions 
of continuous variables, e.g., age and FEV1%, and by treating prior pulmonary exacerbations as a categorical var-
iable. Further, natural day-to-day fluctuations in FEV1%, which may be considered measurement error, could be 
assessed by other methods, such as joint modeling of the longitudinal FEV1% process and the survival process65.
Our study has limitations. The data are derived from non-randomly selected CFFPR participants and thus 
may include biases; however these should not be greater than for our prior work30 and should be reduced by inter-
vening data cleaning1. We excluded patients too young for pulmonary function testing possibly leading to more 
pessimistic survivorship estimates: with current therapies, these patients tend to start and stay in the highest cate-
gories of health and therefore contribute infrequently to deaths in CF2. Higher variation in recording data of some 
variables, such as pancreatic sufficiency status (Fig. 1D) contributes to somewhat larger standard errors in vari-
able estimates (Fig. 3); however, extensive data cleaning did not change our results or interpretations. Methods 
for recording pulmonary exacerbations changed in 2005 which might have changed the impact on survivor-
ship; however, we are confident of the steady decreases in the numbers of pulmonary exacerbations before and 
after 2005 (Fig. 1H). We excluded lung transplantation recipients during each cohort period thus incorporating 
conditioning on a future event. However, reanalysis without transplant exclusions produced similar results with 
no impact on interpretations. (These results are insufficient, however, to allow comment on transplant survival 
effects.) The exclusion from the original 1993 cohort resulted in 5-year survival probabilities that were approxi-
mately 2% over-optimistic relative to observed survival, a bias that was not clinically meaningful in an analysis of 
lung transplantation survival outcomes53. Finally, many patients were eligible for and included in multiple study 
cohorts. This allowed assessments of the potential impacts of intervening data cleaning for cohorts beginning in 
1993. For cohorts non-overlapping in time, inclusion of all eligible patients provided the most appropriate popu-
lation for understanding survival during the specific study period.
We tested the published 5-year predicted survival model of CF derived from a 1993–1997 US cohort of 
patients using new cohorts because new treatments (including CFTR modulators for 2005–2010 and 2011–2016 
cohorts) improved observed mortality rates. Results of re-derivation of 5-year survival models using updated 
cohorts were similar to original results and were stable through multiple sensitivity analyses even when patients 
lost to follow up were reclassified as being among the dead or including patients who received lung transplants 
during each cohort. The original model maintains good calibration and discrimination with new cohorts, espe-
cially in the most recent cohort with modified intercept alone, demonstrating the stability of both the model 
and the underlying disease processes of CF in the face of multiple effective therapies. CFRD is an increasingly 
important detection and treatment target with substantial potential for improving survival with CF. The 5-year 
predicted survival model in original and modified forms remains useful for disease categorization and individ-
ual prognosis, and the demonstrably stable effects of underlying variables provide a foundation for new models 
incorporating extended longitudinal follow up.
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